Evidence map›Paper›PMID 38141777›Full record

ArticleProstaglandins & other lipid mediators2024

12-HETE activates Müller glial cells: The potential role of GPR31 and miR-29.

Mohamed Moustafa, Abraham Khalil, Noureldien H E Darwish, Dao-Qi Zhang, Amany Tawfik, Mohamed Al-Shabrawey

Open access · greenAbstract read
In one paragraph

Article in Prostaglandins & other lipid mediators, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Lipoxin BbioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. The Role of microRNAs Related to Apoptosis forInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mohamed MoustafaEye Research Center, Oakland University William Beaumont School of Medicine (OUWB-SOM), Rochester, MI, USA; Eye Research Institute, Oakland University, Rochester, MI, USA; Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, USA.
Abraham KhalilPhiladelphia College of Osteopathic Medicine, Philadelphia, PA, USA.
Noureldien H E DarwishEye Research Center, Oakland University William Beaumont School of Medicine (OUWB-SOM), Rochester, MI, USA; Eye Research Institute, Oakland University, Rochester, MI, USA; Department of Clinical Pathology, Mansoura College of Medicine, Mansoura University-Egypt.
Dao-Qi ZhangEye Research Center, Oakland University William Beaumont School of Medicine (OUWB-SOM), Rochester, MI, USA; Eye Research Institute, Oakland University, Rochester, MI, USA; Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, USA.
Amany TawfikEye Research Center, Oakland University William Beaumont School of Medicine (OUWB-SOM), Rochester, MI, USA; Eye Research Institute, Oakland University, Rochester, MI, USA; Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, USA.
Mohamed Al-ShabraweyEye Research Center, Oakland University William Beaumont School of Medicine (OUWB-SOM), Rochester, MI, USA; Eye Research Institute, Oakland University, Rochester, MI, USA; Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, USA. Electronic address: malshabrawey@oakland.edu.
Oakland University · USSmith-Kettlewell Eye Research Institute · USPhiladelphia College of Osteopathic Medicine · US

Funding

BMP2/ALKs Signaling System in Diabetic RetinopathyR01EY030054 · NEI · OAKLAND UNIVERSITY · PI Mohamed Al-Sayed Al-Shabrawey · 2020 to 2026
$2.0M
Homocysteine's role in Age-Related Macular DegenerationR01EY029751 · NEI · OAKLAND UNIVERSITY · PI TAWFIK, AMANY M · 2019 to 2023
$1.8M
Role of lipoxygenase pathway in early microvascular dysfunction during diabetic rR01EY023315 · NEI · AUGUSTA UNIVERSITY · PI AL-SHABRAWEY, MOHAMED AL-SAYED · 2013 to 2017
$1.8M
NEI NIH HHS R01 EY023315NEI NIH HHS R01 EY029751NEI NIH HHS R01 EY030054
6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a neurovascular complication of diabetes, driven by an intricate network of cellular and molecular mechanisms. This study sought to explore the mechanisms by investigating the role of 12-hydroxyeicosatetraenoic acid (12-HETE), its receptor GPR31, and microRNA (miR-29) in the context of DR, specifically focusing on their impact on Müller glial cells. We found that 12-HETE activates Müller cells (MCs), elevates glutamate production, and induces inflammatory and oxidative responses, all of which are instrumental in DR progression. The expression of GPR31, the receptor for 12-HETE, was prominently found in the retina, especially in MCs and retinal ganglion cells, and was upregulated in diabetes. Interestingly, miR29 showed potential as a protective agent, mitigating the harmful effects of 12-HETE by attenuating inflammation and oxidative stress, and restoring the expression of pigment epithelium-derived factor (PEDF). Our results underline the central role of 12-HETE in DR progression through activation of a neurovascular toxic pathway in MCs and illuminate the protective capabilities of miR-29, highlighting both as promising therapeutic targets for the management of DR.

Indexed as

Diabetic RetinopathyMicroRNAs12-Hydroxy-5,8,10,14-eicosatetraenoic AcidEpendymoglial CellsReceptors, G-Protein-CoupledRetina12-Hydroxy-5,8,10,14-eicosatetraenoic AcidGPR31 protein, humanMicroRNAsReceptors, G-Protein-Coupled12/15-lipoxygenase12-HETEDiabetic RetinopathyGPR31MiR-29Müller glial cells

Identifiers

PMID38141777
PMCPMC10939904
OpenAlexW4390078628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.